Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension: A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase

By Sica Domenic  

Clinical Drug Investigation, Vol. 31, Iss. 12, 2011-12 ,pp. : 825-837

Adis International

Access to resources Recommend Favorite

Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate: An Open-Label, Parallel-Group, Single-Centre Study

By Stangier Joachim  

Clinical Pharmacokinetics, Vol. 49, Iss. 4, 2010-04 ,pp. : 259-268

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Cinacalcet in Hepatic Impairment: Phase I, Open-Label, Parallel-Group, Single-Dose, Single-Centre Study

By Padhi Desmond  

Clinical Drug Investigation, Vol. 28, Iss. 10, 2008-01 ,pp. : 635-643

Adis International

Access to resources Recommend Favorite

An open‐label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 4, 2015-07 ,pp. : 256-261

John Wiley & Sons Inc

Access to resources Recommend Favorite

Venlafaxine versus Mirtazapine in the Treatment of Undifferentiated Somatoform Disorder: A 12-Week Prospective, Open-Label, Randomized, Parallel-Group Trial

By Han Changsu   Pae Chi-Un   Lee Bun-Hee   Ko Young-Hoon   Masand Prakash S.   Patkar Ashwin A.   Joe Sook-Haeng   Jung In-Kwa  

Clinical Drug Investigation, Vol. 28, Iss. 4, 2008-01 ,pp. : 251-261

Adis International

Access to resources Recommend Favorite